You can buy or sell ABUS and other stocks, options, ETFs, and crypto commission-free!
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Burnaby, British Columbia
52 Week High
52 Week Low
The Motley FoolMar 7
Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
Arbutus Biopharma Corp (NASDAQ:ABUS) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Fourth Quarter and 2018 Year-End Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today's co...
Associated PressMar 7
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/...
Simply Wall StMar 2
The Arbutus Biopharma Share Price Is Down 85% So Some Shareholders Are Rather Upset
Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders should be happy to see the share price up 18% in the last month. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 85%. The recent bounce might mean the long decline is over, but we are not confident. The fundamental business performance will ultimately determine if the turnaround can be sustained. We really feel for...
-$0.37 per share